Modality
siRNA
MOA
Menini
Target
CD3
Pathway
Lipid Met
NASH
Development Pipeline
Preclinical
~Aug 2017
→ ~Nov 2018
Phase 1
Feb 2019
→ Dec 2028
Phase 1Current
NCT08767885
971 pts·NASH
2019-02→2028-12·Not yet recruiting
971 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-072.7y awayPh2 Data· NASH
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P1/2
Not yet…
Catalysts
Ph2 Data
2028-12-07 · 2.7y away
NASH
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08767885 | Phase 1/2 | NASH | Not yet recr... | 971 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 | |
| MDG-4513 | Madrigal Pharma | Phase 1/2 | CD3 | |
| Olpafutibatinib | Immunocore | Approved | SMN2 | |
| SGM-7896 | Sangamo | Preclinical | CD3 |